Dan Samorodnitsky

News Editor

Dan Samorodnitsky is the news editor at BioSpace. He has a decade of experience covering biotech, genetics and medicine. Before coming to BioSpace he was an editor at Drug Discovery News and Massive Science, and his writing has appeared in outlets such as Quanta, STAT, GROW and many others. He is based in Minneapolis. You can reach him at dan.samorodnitsky@biospace.com.

Pictured: Eli Lilly's headquarters in Indianapolis

Deals

Lilly Drops Up To $2.5B for Scorpion’s PI3K-inhibitor Molecule

The multi-billion deal, in which Eli Lilly will acquire Scorpion Therapeutics’ STX-478 program, is a shot in the arm for PI3K treatments, which have had a mixed history over the past few years.

January 13, 2025

2 min read

Dan Samorodnitsky

3D illustration of an antibody-drug conjugate

Antibody-drug conjugates

Merus and Biohaven Strike New ADC Collaboration

On the heels of an FDA approval for its monoclonal antibody Bizengri, Merus will generate three novel cancer-targeting antibodies that it will pass over to Biohaven to link into antibody drug-conjugates.

January 13, 2025

1 min read

Dan Samorodnitsky